First in human phase 1/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cancer (SCLC): phase 1 results
Halperin, DM Johnson, ML Meyer, T Fojo, AT Cook, Natalie Blaszkowsky, LS Schlechter, BL Chan, J Yao, JC Jemiai, Y
Halperin, DM
Johnson, ML
Meyer, T
Fojo, AT
Cook, Natalie
Blaszkowsky, LS
Schlechter, BL
Chan, J
Yao, JC
Jemiai, Y
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Halperin D, Johnson M, Meyer T, Fojo A, Cook N, Blaszkowsky L, et al. First in human phase 1/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cancer (SCLC): phase 1 results. Pancreas. 2019;48(3):436-7.